Methorexate and Knee Osteoarthritis
Primary Purpose
Pain Reduction, Physical Function Improvement
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
25 mg/week oral methotrexate tablets
25mg/week oral placebo tablets
Sponsored by

About this trial
This is an interventional treatment trial for Pain Reduction focused on measuring methotrxate, knee osteoarthritis, inflammation, pain, function
Eligibility Criteria
Inclusion Criteria:
- primary knee osteoarthritis
- synovitis
- pain
Exclusion Criteria:
- other inflammatory conditions
- hepatic insufficiency
- renal insufficiency
Sites / Locations
- Faculty of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Methotrexate
Placebo
Arm Description
25mg oral MTX tablets
25 mg/week placebo tablets
Outcomes
Primary Outcome Measures
Pain reduction
The primary outcome measure was pain reduction.Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm).
Secondary Outcome Measures
Physical function improvement
Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores.
Full Information
NCT ID
NCT04326894
First Posted
August 8, 2013
Last Updated
March 27, 2020
Sponsor
University of Alexandria
1. Study Identification
Unique Protocol Identification Number
NCT04326894
Brief Title
Methorexate and Knee Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
December 2011 (Actual)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alexandria
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Osteoarthritis (OA) is considered a complex, multifactorial disease leading to considerable pain and functional disability amongst older adults in particular.Synovial inflammation and proliferation has emerged as a key component of OA and as a potential predictor of worsening disease. Methotrexate (MTX) is widely used in the treatment of all inflammatory rheumatic diseases. Accordingly, the aim of the present study is to assess the efficacy of methotrexate (MTX) in decreasing pain and inflammation in symptomatic knee OA.
128 patients with clinical and radiographic criteria of primary knee OA pain,were recruited. Patients meeting the eligibility criteria are randomized in a 1:1 ratio to receive either 25mg/week oral MTX (n=64) or placebo (n=64) together with their usual therapy provided the dosages are kept constant for 32 weeks. The primary outcome measure is pain reduction and secondary outcome measures is improvement in physical function scores.
Keywords:
methotrexate knee osteoarthritis inflammation pain reduction physical funtion
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain Reduction, Physical Function Improvement
Keywords
methotrxate, knee osteoarthritis, inflammation, pain, function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
128 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Methotrexate
Arm Type
Experimental
Arm Description
25mg oral MTX tablets
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
25 mg/week placebo tablets
Intervention Type
Drug
Intervention Name(s)
25 mg/week oral methotrexate tablets
Other Intervention Name(s)
interventional drug
Intervention Type
Drug
Intervention Name(s)
25mg/week oral placebo tablets
Primary Outcome Measure Information:
Title
Pain reduction
Description
The primary outcome measure was pain reduction.Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm).
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Physical function improvement
Description
Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores.
Time Frame
8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
primary knee osteoarthritis
synovitis
pain
Exclusion Criteria:
other inflammatory conditions
hepatic insufficiency
renal insufficiency
Facility Information:
Facility Name
Faculty of Medicine
City
Alexandria
ZIP/Postal Code
00203
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Methorexate and Knee Osteoarthritis
We'll reach out to this number within 24 hrs